NO964089L - Farmasöytisk kombinasjonspreparat for hormonell prevensjon - Google Patents

Farmasöytisk kombinasjonspreparat for hormonell prevensjon

Info

Publication number
NO964089L
NO964089L NO964089A NO964089A NO964089L NO 964089 L NO964089 L NO 964089L NO 964089 A NO964089 A NO 964089A NO 964089 A NO964089 A NO 964089A NO 964089 L NO964089 L NO 964089L
Authority
NO
Norway
Prior art keywords
hormone
preparation
pct
estrogen
daily
Prior art date
Application number
NO964089A
Other languages
English (en)
Other versions
NO964089D0 (no
Inventor
Ursula Lachnit
Bernd Dusterberg
Jurgen Spona
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6514578&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO964089(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO964089D0 publication Critical patent/NO964089D0/no
Publication of NO964089L publication Critical patent/NO964089L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Det beskrives et farmasøytisk kombinasjonspreparat med to hormon- . komponenter som er romlig adskilt i en forpakningsenhet, er kondisjo- nert og bestemt for oral admini- strasjon i rekkefølge i tid, hvilke i komponenter består av et antall daglige doseringsenheter som er an- bragt i forpakningsenheten slik at de er romlig adskilt og kan tas ut enkeltvis, hvorved en første av hormonkomponentene som hormonelt, aktivt stoff i kombinasjon innehol- der et østrogenpreparat og et ge- stagenpreparet i enten en- eller , flerfaset utforming i en dosering : som minst er tilstrekkelig til j ovulasjonshemming, og den andre hormonkomponent som hormonelt, ak- tivt stoff utelukkende inneholder i ' et østrogenpreparat, hvor den før- ste hormonkomponent omfatter 23 i i eller 24 og den andre hormonkompo- nent 4 til 8 dagsenheter, idet i dagsenhetene i den første hormon- ; komponent ikke inneholder kombina- i sjonen av et biogent østrogen og ' et syntetisk østrogen, og totalan- tallet hormondagsenheter er likt totalantallet dager for den ønskede syklus, men som minst er 28 dager. Dette kombinasjonspreparat som tjener til fødselskontroll hos kvin- ner, tillater et lavest mulig østrogeninnhold i hver enkelt dose- ringsenhet og har også et lavt total- hormoninnhold pr. administrasjons- ! syklus, ved høy preventiv sikkerhet, liten forekomst av follikkelutvik- ling, upåklagelig sykluskontroll under pålitelig unngåelse av mellom- blødninger så vel som uønskede bivirkninger.
NO964089A 1994-03-30 1996-09-27 Farmasöytisk kombinasjonspreparat for hormonell prevensjon NO964089L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4411585A DE4411585A1 (de) 1994-03-30 1994-03-30 Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
PCT/EP1995/001190 WO1995026730A1 (de) 1994-03-30 1995-03-30 Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption

Publications (2)

Publication Number Publication Date
NO964089D0 NO964089D0 (no) 1996-09-27
NO964089L true NO964089L (no) 1996-11-07

Family

ID=6514578

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964089A NO964089L (no) 1994-03-30 1996-09-27 Farmasöytisk kombinasjonspreparat for hormonell prevensjon

Country Status (25)

Country Link
US (1) US5756490A (no)
EP (1) EP0750501B1 (no)
JP (1) JPH09511243A (no)
KR (1) KR100352571B1 (no)
CN (1) CN1108800C (no)
AT (1) ATE222494T1 (no)
AU (1) AU2073595A (no)
BG (1) BG63192B1 (no)
BR (1) BR9507251A (no)
CA (1) CA2186739A1 (no)
CZ (1) CZ291698B6 (no)
DE (2) DE4411585A1 (no)
DK (1) DK0750501T3 (no)
ES (1) ES2181770T3 (no)
FI (1) FI963831A (no)
HU (1) HUT75521A (no)
NO (1) NO964089L (no)
NZ (1) NZ282824A (no)
PL (1) PL316569A1 (no)
PT (1) PT750501E (no)
RO (1) RO118375B1 (no)
RU (1) RU2165258C2 (no)
SK (1) SK124396A3 (no)
UA (1) UA41401C2 (no)
WO (1) WO1995026730A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
CA2205897A1 (en) * 1994-11-22 1996-05-30 Malcolm Cecil Pike Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
AU726283B2 (en) * 1995-06-28 2000-11-02 Schering Aktiengesellschaft Pharmaceutical combined preparations, kit and method for hormonal contraception
AU2815897A (en) * 1996-05-08 1997-11-26 American Home Products Corporation Oral contraceptive
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
ATE271386T1 (de) * 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
IL127923A (en) * 1996-07-26 2004-07-25 Wyeth Corp Pharmaceutical preparation swallowed to prevent pregnancy
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
UA81387C2 (en) * 1999-08-31 2008-01-10 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1453521B1 (en) 2001-12-05 2013-09-04 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
BRPI0414945A (pt) * 2003-10-01 2006-11-07 Janssen Pharmaceutica Nv regimes contraceptivos trifásicos estendidos
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US20050113350A1 (en) * 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
ES2558030T3 (es) * 2006-03-02 2016-02-01 Warner Chilcott Company, Llc Método anticonceptivo oral multifásico de ciclo prolongado
US11376263B2 (en) 2020-10-08 2022-07-05 Fortress Biotech, Inc. Cyproterone acetate compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6615481A (no) * 1966-11-02 1968-05-03
US3639600A (en) * 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (no) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich

Also Published As

Publication number Publication date
RU2165258C2 (ru) 2001-04-20
BG100940A (en) 1998-03-31
AU2073595A (en) 1995-10-23
CZ291698B6 (cs) 2003-05-14
CN1108800C (zh) 2003-05-21
UA41401C2 (uk) 2001-09-17
NO964089D0 (no) 1996-09-27
FI963831A0 (fi) 1996-09-25
HU9602657D0 (en) 1996-11-28
EP0750501B1 (de) 2002-08-21
FI963831A (fi) 1996-11-29
CN1159161A (zh) 1997-09-10
PT750501E (pt) 2003-01-31
ATE222494T1 (de) 2002-09-15
DE4411585A1 (de) 1995-10-05
HUT75521A (en) 1997-05-28
PL316569A1 (en) 1997-01-20
RO118375B1 (ro) 2003-05-30
US5756490A (en) 1998-05-26
EP0750501A1 (de) 1997-01-02
KR100352571B1 (ko) 2003-01-06
DE59510333D1 (de) 2002-09-26
BG63192B1 (bg) 2001-06-29
CZ287996A3 (en) 1997-02-12
MX9604440A (es) 1997-07-31
BR9507251A (pt) 1997-09-02
DK0750501T3 (da) 2002-12-23
ES2181770T3 (es) 2003-03-01
JPH09511243A (ja) 1997-11-11
NZ282824A (en) 1998-07-28
WO1995026730A1 (de) 1995-10-12
SK124396A3 (en) 1997-05-07
CA2186739A1 (en) 1995-10-12

Similar Documents

Publication Publication Date Title
FI963831A0 (fi) Farmaseuttinen yhdistelmävalmiste hormonaalista ehkäisyä varten
PT835114E (pt) Preparado de combinacao farmaceutico kit e metodo para contracepcao hormonal
ES2086644T5 (es) Preparado anovulatorio para la contracepcion hormonal.
NO974630L (no) Farmasöytisk kombinasjonspreparat for hormonell antikonsepsjon
Van Santen et al. Interception II: postcoital low-dose estrogens and norgestrel combination in 633 women
MXPA01010976A (es) Uso de antiprogestagenos en terapia combinada.